Some studies showed there is no association of LAG‐3 with EGFR status in two prior studies,[256, 257] lower LAG‐3 expression in EGFR‐mutated adenocarcinomas, which is expected given their lower immunogenicity as compared to EGFR‐wild‐type counterparts.[258]. This evidence concerns the gene EGFR and adenocarcinoma.